OncRef

Clinical Trial: NCT05571839

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Status:

TERMINATED

Phase:

Phase 1

Lead Sponsor:Seagen, a wholly owned subsidiary of Pfizer
Information Provided By:Seagen Inc.
Last Update Posted:2026-07-01

Study Overview

Brief Summary

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.

This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Official Title

A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Conditions

Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma

Intervention / Treatment

  • Drug: PF-08046049

Other Study ID Numbers

  • SGNBB228-001
  • C5871001
  • 2022-502348-11-00

Start Date (Actual)

2023-01-03

Primary Completion Date (Actual)

2026-06-01

Study Completion Date (Actual)

2026-06-01

Enrollment (Actual)

41

Study Type

Interventional

Phase

Phase 1